Progyny (NASDAQ:PGNY) Announces Quarterly Earnings Results

Progyny (NASDAQ:PGNY) announced its earnings results on Thursday. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.24), Zacks reports. The firm had revenue of $313.35 million during the quarter, compared to analyst estimates of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 11.23%. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the company earned $0.11 earnings per share. Progyny updated its FY 2025 guidance to 1.790-1.820 EPS and its Q4 2025 guidance to 0.370-0.400 EPS.

Progyny Trading Up 24.2%

Shares of NASDAQ PGNY traded up $4.36 during trading on Friday, reaching $22.37. The company had a trading volume of 4,589,860 shares, compared to its average volume of 1,669,160. The stock has a market capitalization of $1.92 billion, a PE ratio of 35.51, a price-to-earnings-growth ratio of 1.53 and a beta of 1.29. The stock has a 50-day moving average price of $20.91 and a two-hundred day moving average price of $21.85. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,895 shares of company stock worth $179,311. 9.40% of the stock is owned by company insiders.

Institutional Trading of Progyny

A number of institutional investors have recently modified their holdings of the company. Canada Pension Plan Investment Board purchased a new stake in Progyny during the 2nd quarter worth $77,000. Tower Research Capital LLC TRC lifted its stake in shares of Progyny by 203.5% during the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after purchasing an additional 4,708 shares in the last quarter. Teza Capital Management LLC boosted its position in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after buying an additional 516 shares during the period. Amundi grew its stake in shares of Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after buying an additional 5,817 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in shares of Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after buying an additional 780 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price target on Progyny from $23.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, August 26th. Raymond James Financial set a $28.00 price objective on Progyny in a research note on Friday, August 8th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 target price (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.44.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.